These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 34655050)

  • 1. Effects of Letermovir and/or Methylprednisolone Coadministration on Voriconazole Pharmacokinetics in Hematopoietic Stem Cell Transplantation: A Population Pharmacokinetic Study.
    Suetsugu K; Muraki S; Fukumoto J; Matsukane R; Mori Y; Hirota T; Miyamoto T; Egashira N; Akashi K; Ieiri I
    Drugs R D; 2021 Dec; 21(4):419-429. PubMed ID: 34655050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation.
    Nakashima T; Inamoto Y; Fukushi Y; Doke Y; Hashimoto H; Fukuda T; Yamaguchi M
    Int J Hematol; 2021 Jun; 113(6):872-876. PubMed ID: 33677768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decrease in voriconazole concentration-to-dose ratio after letermovir initiation: a retrospective, observational study.
    Hikasa S; Shimabukuro S; Osugi Y; Ikegame K; Kaida K; Fukunaga K; Higami T; Tada M; Tanaka K; Yanai M; Kimura T
    Bone Marrow Transplant; 2021 Apr; 56(4):949-951. PubMed ID: 33100323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Tolerability of Letermovir Coadministered With Azole Antifungals (Posaconazole or Voriconazole) in Healthy Subjects.
    Marshall WL; McCrea JB; Macha S; Menzel K; Liu F; van Schanke A; de Haes JIU; Hussaini A; Jordan HR; Drexel M; Kantesaria BS; Tsai C; Cho CR; Hulskotte EGJ; Butterton JR; Iwamoto M
    J Clin Pharmacol; 2018 Jul; 58(7):897-904. PubMed ID: 29578577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal.
    Nakashima T; Inamoto Y; Aoki J; Ito A; Tanaka T; Kim SW; Hashimoto H; Fukuda T; Furukawa T
    Int J Hematol; 2022 Feb; 115(2):158-162. PubMed ID: 35088349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Pharmacokinetic Interaction Between Letermovir and Tacrolimus in Allogeneic Hematopoietic Cell Transplantation Recipients.
    Marciano KA; Seago K; Dillaman M; Ross KG; Veltri L; Cumpston A
    Transplant Cell Ther; 2022 Jul; 28(7):371.e1-371.e4. PubMed ID: 35405369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Letermovir and tacrolimus interaction effects in hematopoietic cell transplantation recipients receiving moderate cytochrome P450 3A4 inhibitors for antifungal prophylaxis.
    Malespini J; Lei M; Tavares E; Hammond SP; Chen YB; Luk SO; DeFilipp Z
    J Oncol Pharm Pract; 2023 Oct; 29(7):1574-1579. PubMed ID: 36398324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients.
    Prohn M; Viberg A; Zhang D; Dykstra K; Davis C; Macha S; Sabato P; de Alwis D; Iwamoto M; Fancourt C; Cho CR
    CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):255-267. PubMed ID: 33440077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of letermovir initiation on tacrolimus concentrations among lung transplant recipients receiving concomitant azole antifungal prophylaxis.
    Goodlet KJ; Garcia R
    Transpl Infect Dis; 2024 Apr; 26(2):e14267. PubMed ID: 38488776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study.
    Hikasa S; Shimabukuro S; Osugi Y; Ikegame K; Kaida K; Fukunaga K; Higami T; Tada M; Tanaka K; Yanai M; Kimura T
    Int J Med Sci; 2020; 17(7):859-864. PubMed ID: 32308538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing.
    Patel JN; Robinson M; Morris SA; Jandrisevits E; Lopes KE; Hamilton A; Steuerwald N; Druhan LJ; Avalos B; Copelan E; Ghosh N; Grunwald MR
    Pharmacogenomics J; 2023 Nov; 23(6):201-209. PubMed ID: 37925536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients.
    Zhou H; Gao Y; Cheng XL; Li ZD
    Eur J Drug Metab Pharmacokinet; 2012 Dec; 37(4):271-8. PubMed ID: 22446981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir.
    Terrier J; Zanella MC; Masouridi-Levrat S; Kronig I; Chalandon Y; Vernaz N; Van Delden C; Papanicolaou G; Neofytos D
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants.
    Adedoyin A; Fancourt C; Menzel K; Zhao T; Tomek C; Panebianco D; McCrea JB; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2021 Feb; 10(2):198-206. PubMed ID: 32700459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
    Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
    Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-center experience with use of letermovir for treatment of CMV infection in stem cell transplant recipients.
    Kachur E; Roshdy D; Hamadeh I; Dodd B; Shahid Z
    Transpl Infect Dis; 2021 Apr; 23(2):e13502. PubMed ID: 33171005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation.
    Chen C; Yang T; Li X; Ma L; Liu Y; Zhou Y; Ren H; Cui Y
    Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):659-668. PubMed ID: 31041728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.
    Ceberio I; Dai K; Devlin SM; Barker JN; Castro-Malaspina H; Goldberg JD; Giralt S; Adel NG; Perales MA
    Bone Marrow Transplant; 2015 Mar; 50(3):438-43. PubMed ID: 25599164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the
    Ling J; Yang X; Dong L; Jiang Y; Zou S; Hu N
    Front Pharmacol; 2024; 15():1455721. PubMed ID: 39228522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation.
    Deleenheer B; Spriet I; Maertens J
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1197-1207. PubMed ID: 30479172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.